

HER2 (ErbB2) positive breast cancer whose disease had progressed following treatment with trastuzumab and other cancer therapies. The hazard ratio of 0.57 (95% CI: 0.43, 0.77,  $p = 0.00013$ ) represents a 43 percent reduction in the risk of progression for the patients on the combination arm.<sup>1</sup> Differences between treatment groups based on unblinded investigator assessments were smaller but continued to be clinically and statistically significant.

Adverse events (AEs) leading to discontinuation were similar in the

TYKERB-capecitabine combination arm (14 percent) versus capecitabine alone (14 percent). Most commonly reported AEs in the TYKERB-capecitabine combination arm included diarrhea, hand-foot syndrome, nausea, rash, vomiting and fatigue. Left ventricular ejection fraction (LVEF), a measure of the strength of the heart's pumping capacity, was monitored during the study. Among 198 patients who received the TYKERB-capecitabine combination treatment, three experienced an asymptomatic (grade 2) decrease in LVEF and one experienced a symptomatic (grade 3) decrease in LVEF.

### Ongoing Trials

GSK has a comprehensive clinical program that is actively studying TYKERB in other breast cancer settings and other cancers to better identify patient populations that may respond to TYKERB.

Marketing applications for lapatinib (TYKERB/TYVERB) have been filed around the world, including the European Union, Switzerland, Canada, Brazil, Australia, and South Korea.

Visit [www.tykerb.com](http://www.tykerb.com) for full prescribing information. **OA**

## Important Procrit Safety Update

If you are prescribing PROCIT<sup>®</sup>, there is new safety information that could affect your patients.

Safety information has emerged reinforcing the importance of using the lowest dose of PROCIT that will gradually increase the hemoglobin concentration to the lowest level sufficient to avoid the need for red blood cell transfusion.

If you are currently using PROCIT to treat any of your anemic patients, please visit [www.procrit.com](http://www.procrit.com) and review the full Prescribing Information, including the Boxed WARNINGS.